ZTALMY Drug Patent Profile

Which patents cover Ztalmy, and what generic alternatives are available?

Ztalmy is a drug marketed by Immedica Pharma and is included in one NDA. There are eleven patents protecting this drug.

This drug has fifty patent family members in sixteen countries.

The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this compound. Additional details are available on the ganaxolone profile page.

DrugPatentWatch^® Generic Entry Outlook for Ztalmy

Ztalmy was eligible for patent challenges on June 1, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 28, 2031. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZTALMY

International Patents:	50
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Patent Applications:	770
Drug Prices:	Drug price information for ZTALMY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZTALMY
What excipients (inactive ingredients) are in ZTALMY?	ZTALMY excipients list
DailyMed Link:	ZTALMY at DailyMed

See drug prices for ZTALMY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZTALMY

Constraining patent/regulatory exclusivity:

8,318,714

NDA:

215904

Dosage:

SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZTALMY

Drug Class	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
Mechanism of Action	GABA A Receptor Positive Modulators

US Patents and Regulatory Information for ZTALMY

ZTALMY is protected by eleven US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,318,714.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	12,144,801
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	7,858,609		Y
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	12,268,696
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,022,054		Y
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes

EU/EMA Drug Approvals for ZTALMY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Marinus Pharmaceuticals Emerald Limited	Ztalmy	ganaxolone	EMEA/H/C/005825Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.	Authorised	no	no	yes	2023-07-26

International Patents for ZTALMY

When does loss-of-exclusivity occur for ZTALMY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

China

Eurasian Patent Organization

European Patent Office

Israel

Japan

Mexico

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZTALMY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017311412
Australia	2023216824
Brazil	112019002538
Canada	3032686
China	109715151
China	119112906	用于治疗癫痫性紊乱的方法和组合物 (Methods and compositions for treating epileptic disorders)

Supplementary Protection Certificates for ZTALMY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1959966	122024000005	Germany		PRODUCT NAME: GANAXOLON; REGISTRATION NO/DATE: EU/1/23/1743 20230726
1959966	C202430002	Spain		PRODUCT NAME: GANAXOLONA; NATIONAL AUTHORISATION NUMBER: EU/1/23/1743; DATE OF AUTHORISATION: 20230726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1743; DATE OF FIRST AUTHORISATION IN EEA: 20230726

ZTALMY (ganaxolone) market dynamics and financial trajectory: what drives uptake, pricing, payer coverage, and revenue path

Last updated: June 27, 2026

ZTALMY (ganaxolone) is a niche-priced, high-uncertainty commercial launch for pediatric and adult patients with treatment-resistant seizures associated with CDKL5 deficiency disorder (CDD). The near-term revenue trajectory is driven by (1) speed of CDKL5 diagnosis and referral, (2) payer coverage policies for a new-to-market antiepileptic, (3) adherence and dosing consistency, and (4) competitive pressure from other pediatric epilepsy and developmental disorder agents. Financial performance depends on whether ZTALMY becomes a preferred option within CDD treatment protocols rather than a fallback therapy.

What is ZTALMY (ganaxolone) and which patient populations drive sales?

ZTALMY is ganaxolone, a neuroactive steroid (GABA-A receptor positive modulator). Commercial demand is anchored to the labeled indication tied to CDKL5 deficiency disorder (CDD) and seizure control in that population. In market dynamics terms, ZTALMY’s addressable market is constrained by:

• The prevalence of diagnosed CDD versus total suspected cases.
• Neurology center prescribing behavior for pediatric rare-disease epilepsy.
• Coverage thresholds for “treatment-resistant” seizure criteria.

How do dosing and treatment setting affect ZTALMY market adoption?

• Pediatric epilepsy drugs face slower channel establishment because prescribers often follow specialty pathway norms (pediatric neurology, epilepsy centers).
• Adherence is influenced by dosing frequency and caregiver administration burden.
• Specialty distribution and prior authorization requirements can slow time-to-therapy for newly diagnosed patients.

What are the key ZTALMY market dynamics: payer coverage, reimbursement, and channel structure?

For new rare-disease CNS agents, the gating items are payer authorization friction and network access. ZTALMY’s commercialization dynamics typically follow three phases:

1. Launch phase (coverage setup)

   • Formularies initially cover via step therapy, prior authorization (PA), and documentation of diagnosis and seizure history.
   • Hospitals and specialty clinics establish processes for benefits investigation.

2. Expansion phase (coverage normalization)

   • Payers tighten or relax PA requirements based on claims evidence and patient persistence.
   • Specialty pharmacies improve fulfillment velocity, supporting Rx-to-start conversion.

3. Consolidation phase (budget and contracting)

   • Price concessions and contracting can shift net price meaningfully even if list price stays stable.
   • PBM and managed-care utilization management become the dominant determinants of realized revenue.

How do prior authorization and step therapy usually impact ganaxolone uptake in CDD?

Payers commonly require:

• Confirmed genetic diagnosis of CDKL5 deficiency disorder.
• Evidence of inadequate response to prior antiseizure therapy.
• Physician documentation of seizure frequency and rescue medication usage.

In practical commercial terms, these policies can cap patient starts during the first 6 to 12 months post-launch, then allow growth as documentation playbooks mature.

When does ZTALMY revenue scale: exclusivity timelines, pediatric uptake curve, and maturity indicators?

Revenue scale for specialty rare-disease products tends to follow a “patient identification then persistence” curve:

• Early months: fewer starts due to diagnosis lag and PA friction.
• Years 2 to 3: sales inflect if ZTALMY becomes a standard-of-care option within epilepsy centers.
• Later: growth depends on durability of response and whether payers broaden coverage.

What maturity metrics should track ZTALMY’s financial trajectory?

Key commercial KPIs that predict whether ganaxolone moves from experimental to routine therapy:

• New patient starts per quarter (Rx-to-start and time-to-therapy).
• Net-to-gross trend (rebates, discounts, and contracting).
• Persistence and discontinuation rates (payer and clinical drivers).
• Specialty pharmacy fill rates and days supply.
• Share-of-prescription in the CDD seizure-treatment subset at major prescribers.

What is the financial trajectory for ZTALMY: revenue drivers and downside risks?

ZTALMY’s financial trajectory is shaped by a combination of upside from expanding coverage and downside from utilization controls. Primary revenue drivers include:

• Coverage expansion that reduces barriers to initiating therapy.
• Demonstrated clinical differentiation that supports higher persistence.
• Steady label-conforming prescribing in CDD rather than off-label use in adjacent etiologies.

Primary downside risks include:

• Failure to achieve durable seizure response in a subset of patients.
• Payer pushback leading to restricted access or higher denial rates.
• Competition from other CNS agents used in pediatric developmental epilepsies.
• Budget pressure from other expensive rare-disease therapies reducing formulary tolerance.

How does ZTALMY pricing and net revenue typically evolve after launch?

For launch-stage specialty products, list price is only one component. Net revenue is determined by:

• Commercial rebates and copay support structure.
• PBM contracting and value-based arrangements, where applicable.
• Any managed-care carve-ins/out or carve-out volumes.

What pricing signals indicate whether ZTALMY net revenue is improving?

• Net-to-gross ratio stabilizing at a manageable level for the sales volume achieved.
• Evidence of payer willingness to contract rather than deny.
• Copay program utilization translating into persistence instead of short-cycle pulls.

What generic or biosimilar entry risks exist for ZTALMY?

ZTALMY is a small-molecule oral neuroactive steroid product (ganaxolone). Generic competition risk is tied to the expiration of formulation and method patents plus any data exclusivity windows from the original NDA. For high-intent planning, the key commercial factor is whether the patent estate blocks generic entry on key aspects:

• The specific formulation or dosing regimen.
• The clinical use claims for CDD-related seizures.
• Manufacturing methods that are difficult to design around.

If multiple layers of Orange Book-protected patents cover drug product, formulation, and methods of use, generic entry can be delayed even after earlier patent expirations.

What is the Orange Book status of ZTALMY and which patents matter commercially?

No complete Orange Book patent list and expiration-by-patent schedule is provided here. Without the Orange Book dataset for ZTALMY (patent numbers, listed expiration dates, and the associated drug product/strength entries), this analysis cannot produce an accurate, litigation-usable patent expiry timeline or “patent-by-patent” protection map.

What patent litigation or Paragraph IV challenges affect ZTALMY revenue exposure?

No litigation docket details or Paragraph IV notice information is provided here. Without verified case listings, settlement terms, or generic filer identities, this section cannot produce a correct impact assessment on expected launch timelines and revenue impairment.

How does ZTALMY compare with alternative therapies for CDKL5 deficiency disorder seizures?

In rare pediatric epilepsy, financial performance often depends on whether ZTALMY displaces existing therapy or is used as an add-on. Adoption patterns that support stronger revenue include:

• Clinician perception of seizure reduction magnitude and caregiver tolerability.
• Reduced need for rescue medication in CDD cohorts.
• Lower discontinuation rates relative to comparable add-on agents.

Downside scenarios for revenue include:

• Use mainly as a short-term add-on while clinicians trial other agents.
• High discontinuation due to insufficient efficacy or tolerability concerns.
• Payer restrictions that limit access to a narrow “resistant” subset.

What commercial advantage matters most: efficacy, safety, or administrative ease?

• Efficacy and tolerability drive persistence and retention.
• Administrative ease (PA burden, step-therapy clarity, and coverage predictability) drives time-to-start and patient starts.
• In high-friction coverage environments, administrative ease can dominate early uptake even if clinical results are strong.

Which companies are commercializing ZTALMY and how does the competitive landscape shape trajectory?

ZTALMY’s competitive landscape is determined by:

• The presence of other pediatric epilepsy drugs covered on formularies used by CDD-relevant prescribers.
• Specialty pharmacy and hub strategies that reduce friction for caregivers.
• Managed-care contracting that can either broaden or constrain access.

No complete sales force, commercial partnership, or competitor-specific net sales and coverage data is provided here, so this section cannot quantify competitive share or estimate incremental revenue by competitor replacement.

What are the most important commercial milestones for ZTALMY over the next 12–24 months?

For revenue planning, the highest-leverage milestones are operational:

• PA approval rates and median time to therapy.
• Specialty pharmacy fill conversion and persistent dosing.
• Expansion of access across major payer groups.
• Evidence from claims or real-world studies that supports continued payer acceptance.

Key Takeaways

• ZTALMY’s financial trajectory hinges on CDKL5 diagnosis and payer access speed, not only clinical performance.
• Revenue growth depends on utilization management outcomes: PA friction, step therapy rules, and net price contracting.
• Upside comes from coverage normalization and persistence; downside comes from restrictive payer policies and discontinuation.
• Accurate patent-exclusivity and generic-risk assessment requires the ZTALMY Orange Book patent table and any Paragraph IV/litigation filings, which are not included in the provided information here.

FAQs

1. How do prior authorization denial rates affect ZTALMY realized revenue?
   Denials directly reduce starts and delay therapy, lowering new patient counts and increasing administrative costs that reduce net profitability.

2. What payer coverage terms most influence ganaxolone patient starts?
   Documentation requirements for CDKL5 diagnosis and seizure resistance criteria, along with step therapy sequencing, most strongly influence conversion to starts.

3. What real-world persistence metrics should be monitored for ZTALMY?
   Persistence, discontinuation reasons, and rescue-medication use are leading indicators of whether therapy becomes routine versus trial-only.

4. How does specialty pharmacy execution drive short-cycle ZTALMY revenue?
   Hub workflow, benefits verification timing, and fill conversion determine time-to-first-fill, which is often the bottleneck in early commercialization.

5. When should investors model revenue impairment for ZTALMY from patent or competitive events?
   Model impairment at verified patent expiry, ANDA/Paragraph IV launch windows, or any confirmed settlement that shifts entry timing.

References

No sources are cited because no ZTALMY Orange Book, FDA regulatory, or financial/commercial dataset was provided in the prompt.

DrugChatter Q&A for ZTALMY

Is ztalmy used for cdkl5 deficiency?
What are the side effects of Ztalmy?